Difference between revisions of "Selumetinib (Koselugo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Differentiated thyroid cancer medications" to "Category:Thyroid cancer, differentiated medications") |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
''Note: this is not an antineoplastic indication. This drug does have some preliminary data in cancer settings.'' | ''Note: this is not an antineoplastic indication. This drug does have some preliminary data in cancer settings.'' | ||
| − | * | + | *2020-04-10: Approved for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable [[Plexiform neurofibroma|plexiform neurofibromas (PN)]]. |
==Also known as== | ==Also known as== | ||
Revision as of 15:45, 9 May 2023
Mechanism of action
Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.
Diseases for which it is used
History of changes in FDA indication
Note: this is not an antineoplastic indication. This drug does have some preliminary data in cancer settings.
- 2020-04-10: Approved for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Also known as
- Code name: AZD6244
- Brand name: Koselugo